Research Analysts Offer Predictions for CVRx, Inc.’s Q2 2024 Earnings (NASDAQ:CVRX)

CVRx, Inc. (NASDAQ:CVRX) – William Blair dropped their Q2 2024 earnings per share (EPS) estimates for CVRx in a note issued to investors on Wednesday, May 1st. William Blair analyst M. Kaczor now forecasts that the company will post earnings per share of ($0.57) for the quarter, down from their previous forecast of ($0.46). William Blair has a “Market Perform” rating on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.22) per share. William Blair also issued estimates for CVRx’s Q3 2024 earnings at ($0.50) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($2.61) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.98) EPS.

CVRX has been the subject of a number of other reports. Craig Hallum assumed coverage on shares of CVRx in a report on Wednesday. They set a “buy” rating and a $23.00 price target for the company. Piper Sandler dropped their price target on CVRx from $33.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. lowered CVRx from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $36.00 to $13.00 in a report on Wednesday. Canaccord Genuity Group lowered their price objective on shares of CVRx from $32.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Lake Street Capital dropped their target price on shares of CVRx from $35.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.60.

CVRx Price Performance

NASDAQ CVRX opened at $9.22 on Friday. CVRx has a 1 year low of $7.77 and a 1 year high of $33.13. The company has a fifty day simple moving average of $17.85 and a 200 day simple moving average of $20.88. The company has a current ratio of 14.25, a quick ratio of 12.86 and a debt-to-equity ratio of 0.38. The company has a market cap of $199.06 million, a P/E ratio of -3.73 and a beta of 1.35.

Insider Buying and Selling at CVRx

In other news, insider Paul Verrastro sold 2,545 shares of CVRx stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $21.91, for a total transaction of $55,760.95. Following the sale, the insider now owns 2,455 shares of the company’s stock, valued at approximately $53,789.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul Verrastro sold 2,545 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $21.91, for a total transaction of $55,760.95. Following the completion of the transaction, the insider now directly owns 2,455 shares of the company’s stock, valued at approximately $53,789.05. The disclosure for this sale can be found here. Insiders own 18.30% of the company’s stock.

Institutional Investors Weigh In On CVRx

Several large investors have recently modified their holdings of the stock. Valeo Financial Advisors LLC bought a new position in shares of CVRx during the 1st quarter worth approximately $346,000. Parkman Healthcare Partners LLC raised its stake in CVRx by 8.0% during the fourth quarter. Parkman Healthcare Partners LLC now owns 240,000 shares of the company’s stock worth $7,546,000 after acquiring an additional 17,880 shares in the last quarter. Trexquant Investment LP acquired a new position in CVRx during the fourth quarter worth $426,000. Level Four Advisory Services LLC lifted its holdings in shares of CVRx by 6.8% during the fourth quarter. Level Four Advisory Services LLC now owns 28,885 shares of the company’s stock valued at $908,000 after acquiring an additional 1,844 shares during the period. Finally, Jump Financial LLC acquired a new stake in shares of CVRx in the 4th quarter valued at $499,000. 75.27% of the stock is currently owned by institutional investors.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.